|
HCV
News
Week
Ending 12/28/2014
The Winner of the
AbbVie-Gilead Hep-C Battle? Express Scripts
'Leerink's
David Larsen and Chris Abbott point to the one definite winner in the
battle between Gilead Sciences (GILD) and AbbVie (ABBV) for hepatitis-C
supremacy: Express Scripts (ESRX). They explain:
"This
morning Express Scripts announced that it has struck a multi-year deal
with AbbVie, making Viekira Pak the exclusive option for Genotype 1
Hepatitis C patients covered by the Express Scripts National Preferred
Formulary."'
PBM deal on new hep.-C
cocktail highlights drugmaker tolerance for discounts
'Thanks
to a discounting assist from AbbVie, Express Scripts wasted no time
following through on a pledge to favor the company's hepatitis C
cocktail, assuming efficacy and costs comparable to Gilead's Sovaldi
and Harvoni.'
Opioid use lowered HCV
incidence in young adult injection drug users
'Young
adult injection drug users showed a decreased incidence rate for
hepatitis C virus infection after undergoing maintenance opioid agonist
treatment, according to study data. Researchers, including Judith I.
Tsui, MD, MPH, of the department of medicine at Boston University
School of Medicine, conducted an observational cohort study with 552
injection drug users from San Francisco negative for anti-HCV antibody
or HCV RNA between 2000 and August 2013.'
Genes show the way to better
treatment of hepatitis A
'One
of the most common causes of hepatitis A (formerly known as infectious
hepatitis) is a hepatitis C virus infection in the liver. The disease
can be treated medically, but not all patients are cured by the
treatment currently available. New research shows that the response to
medical treatment depends on genetic factors.'
The Hepatitis C Drug
Developer That Crushed Gilead Sciences, Inc. in 2014 (Hint: It's Not
AbbVie)
'For
shareholders of Gilead Sciences (NASDAQ: GILD ) it's practically been a
dream year. Shares rose close to 40%, tacking on roughly $45 billion in
market value, following the successful approval and launch of oral
hepatitis C drugs Sovaldi and Harvoni.'
|
